.3The Phase 3 TIDES trial is Takeda’s largest interventional clinical trial to date. Takeda and an independent Data Monitoring Committee of experts are actively monitoring safety on an ongoing basis.

About QDENGA®▼ (Dengue Tetravalent Vaccine [Live, Attenuated])

QDENGA®(TAK-003) is a dengue vaccine that is based on a live-attenuated dengue serotype 2 virus, which provides the genetic “backbone” for all four dengue virus serotypes and is designed to help protect against any of these serotypes.6

In the European Union (EU) Member States, QDENGA is indicated for the prevention of dengue disease in individuals from four years of age and should be administered subcutaneously as a 0.5 mL dose at a two-dose (0 and 3 months) schedule pursuant to approved dosing regimen.7

Always consult your local prescribing information before prescribing. The local label may vary.

Important Safety Information

Please consult t
=*=*=*=*=*=
当前为第7/21页
下一页-上一页-
=*=*=*=*=*=
返回新闻列表
返回网站首页